Introduction And Epidemiology

  • Kawasaki disease presenting with partial clinical criteria.
  • Defined by unexplained fever lasting five or more days associated with only two or three classic clinical features.
  • Highly prevalent in young infants under six months of age.
  • Infant presenting with unexplained fever for seven or more days without apparent focus mandates immediate echocardiographic evaluation.
  • Demonstrates profoundly higher risk for coronary artery abnormalities secondary to delayed clinical recognition.
  • Clinical features frequently evolute sequentially over days, obscuring timely diagnosis.

Atypical Clinical Manifestations

  • Standard mucocutaneous signs remain frequently absent, subtle, or fleeting.
  • Reactivation of bacillus Calmette-Guerin inoculation site exhibits profound erythema and induration.
  • Extreme irritability acts as prominent clinical clue, occurring secondary to aseptic meningitis.
  • Node-first presentation manifests as isolated, unilateral, tender cervical lymphadenopathy.
  • Neck ultrasonography reveals uniformly hypoechoic nodes lacking necrosis, demonstrating well-circumscribed margins termed cluster of grapes appearance.
  • Acute hydrocele presents as sudden, painful unilateral scrotal swelling.
  • Hydrops of gallbladder presents as upper abdominal mass, mimicking acute surgical abdomen.
  • Perianal erythema with profound desquamation occurs frequently during acute disease phase.

Diagnostic Evaluation Algorithm

  • Lacks pathognomonic diagnostic laboratory test.
  • Evaluation strictly triggered when C-reactive protein equals or exceeds 3.0 mg/dL, or erythrocyte sedimentation rate equals or exceeds 40 mm/hr.
  • Diagnosis established utilizing standardized diagnostic algorithms integrating supplemental laboratory and echocardiographic parameters.

Supplemental Laboratory Criteria

  • Presence of three or more supplemental laboratory criteria establishes positive diagnostic threshold.
BiomarkerDiagnostic Threshold
HemoglobinAnemia for age.
Platelet CountGreater than or equal to 450,000 per cubic millimeter after seventh day of fever.
Serum AlbuminLess than or equal to 3.0 g/dL.
Hepatic EnzymesElevated alanine aminotransferase.
LeukocytesWhite blood cell count greater than or equal to 15,000 per cubic millimeter.
UrinalysisGreater than or equal to 10 white blood cells per high-power field indicating sterile pyuria.

Echocardiographic Diagnostic Criteria

  • Echocardiogram considered positive for incomplete disease if specific structural or functional conditions met.
Finding CategorySpecific Diagnostic Conditions
Coronary DilationZ score of left anterior descending or right coronary artery equals or exceeds 2.5.
Direct ObservationCoronary artery aneurysm directly visualized.
Suggestive FeaturesPresence of three or more subtle criteria establishes positive scan. Includes perivascular brightness, lack of vessel tapering. Includes decreased left ventricular function, mitral regurgitation, pericardial effusion. Includes Z scores in left anterior descending or right coronary artery between 2.0 and 2.5.

Advanced Biomarkers

  • N-terminal pro-B-type natriuretic peptide levels exceeding 500 pg/mL strongly assist diagnostic confirmation in ambiguous presentations.
  • Gamma-glutamyl transferase elevation occurs notably without frank hepatic dysfunction.

Differential Diagnosis

  • Presentation mimics multiple infectious, rheumatologic, and hyperinflammatory syndromes.
Disease CategoryDistinguishing Clinical And Laboratory Features
Multisystem Inflammatory Syndrome In ChildrenOccurs post-SARS-CoV-2 infection. Affects older demographic. Features profound gastrointestinal pain, severe myocardial dysfunction, profound lymphopenia, marked hyperferritinemia.
Systemic Juvenile Idiopathic ArthritisFeatures quotidian fever pattern. Exhibits prominent hepatosplenomegaly. Lacks coronary artery aneurysms classically.
Adenovirus InfectionDemonstrates prominent exudative pharyngitis and exudative conjunctivitis.
Scarlet FeverYields rapid clinical response to appropriate antibiotic therapy. Demonstrates elevated anti-streptolysin O titers and sandpaper rash.
Macrophage Activation SyndromeFeatures unremitting fever, profound hepatosplenomegaly. Laboratory profile reveals paradoxically dropping erythrocyte sedimentation rate, extreme hyperferritinemia, hypofibrinogenemia.

Management Strategies

  • Mandates immediate therapeutic intervention to halt progressive coronary architecture damage.
  • Intravenous immunoglobulin 2 g/kg administered as single continuous infusion over 8 to 12 hours.
  • Aspirin therapy initiated concurrently.
  • Recent 2024 guidelines advocate low-dose aspirin 3 to 5 mg/kg/day from onset to minimize gastrointestinal bleeding risks.
  • Antiplatelet aspirin continued minimum 6 to 8 weeks.
  • Discontinue aspirin entirely if serial echocardiograms remain completely normal.
  • Live viral vaccines deferred for 11 months following intravenous immunoglobulin administration.

Intensification And Refractory Therapy

  • High-risk patients require immediate intensification of primary regimen.
  • Infants under six months uniformly require intensification due to exceptional aneurysm risk approaching 43%.
  • Baseline coronary artery Z score exceeding 2.5 strictly mandates intensification.
  • Corticosteroids utilize intravenous methylprednisolone 2 mg/kg/day divided every 12 hours.
  • Infliximab 10 mg/kg infused over 2 hours serves as potent biological alternative.
  • Intravenous immunoglobulin resistance defined strictly as persistent or recrudescent fever 36 hours post-infusion.
  • Resistance necessitates prompt administration of second intravenous immunoglobulin dose, pulse corticosteroids, or calcineurin inhibitors including cyclosporine.
  • Statins (75 mg/kg/day) modulate endothelial function, block endothelial to mesenchymal transition, and reduce oxidative stress in persistent disease.

Complications And Prognosis

  • Delayed clinical diagnosis independently drives highest rates of coronary artery aneurysms in infants.
  • Giant aneurysms (Z score greater than or equal to 10) carry lifetime risk of occlusive thrombosis, myocardial infarction, and sudden death.
  • Giant aneurysms necessitate lifelong dual antiplatelet therapy coupled with systemic anticoagulation utilizing low molecular weight heparin or direct oral anticoagulants.
  • Myocardial infarction risk peaks dramatically during first 2 to 3 months following illness onset.
  • Complete regression of small aneurysms occurs frequently, carrying near-zero long-term risk of adverse cardiac events.
  • Regressed large aneurysms maintain permanent myointimal thickening and abnormal vascular reactivity indefinitely.
  • Mandatory long-term surveillance incorporates advanced imaging modalities including computed tomography angiography or magnetic resonance imaging to detect progressive luminal stenosis.